Cadrenal Therapeutics, Inc. Common Stock
NASDAQ: CVKD0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Quang X. Pham
- Employees
- 4
- Headquarters
- Ponte Vedra, United States
- IPO year
- 2023
- Market cap
- $9.2M
- Website
- https://www.cadrenal.com
Loading CVKD…
Loading profile data…Frequently asked questions about CVKD
What does Cadrenal Therapeutics, Inc. Common Stock (CVKD) do?
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patie...
Where does CVKD trade?
Cadrenal Therapeutics, Inc. Common Stock (CVKD) trades on the NASDAQ Global Market.
What sector is CVKD in?
Cadrenal Therapeutics, Inc. Common Stock (CVKD) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Cadrenal Therapeutics, Inc. Common Stock?
Quang X. Pham is the chief executive officer of Cadrenal Therapeutics, Inc. Common Stock (CVKD).
Where is Cadrenal Therapeutics, Inc. Common Stock headquartered?
Cadrenal Therapeutics, Inc. Common Stock is headquartered in United States.
Does CVKD pay a dividend?
Cadrenal Therapeutics, Inc. Common Stock (CVKD) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CVKD go public?
Cadrenal Therapeutics, Inc. Common Stock (CVKD) completed its initial public offering in 2023.